Enantone 1-Month DPS 3.75 mg/Enantone 3-Month DPS 11.25 mg/Enantone 6-Month DPS 30 mg Use In Pregnancy & Lactation

Enantone 1-Month DPS 3.75 mg: Endometriosis, Uterine Myoma, Premenopausal Breast Cancer, Central Precocious Puberty: ENANTONE should not be administered to pregnant women, women having possibilities of being pregnant, or nursing mothers. Abortion due to LH-RH derivatives has been reported. In animal studies of this drug, increased fetal death rate and low fetal body weight were observed (in rats and rabbits), and an increasing tendency for abnormal formation of fetal skeleton was observed (in rabbits). The transfer of Leuprorelin Acetate to mother's milk was also observed in rats.
Enantone 3-Month DPS 11.25 mg: Pregnancy: Enantone must not be administered during pregnancy (see Contraindications). Women of childbearing potential must use non-hormonal contraceptive measures during the treatment and until the menstrual cycle is resumed. Prior to treatment, women of childbearing potential should be carefully monitored to rule out an ongoing pregnancy.
Breastfeeding: Enantone should not be used during breastfeeding (see Contraindications).
Enantone 6-Month DPS 30 mg: ENANTONE 6 MONTH DPS is not intended for the use in women and is generally contraindicated during pregnancy and lactation.
Fertility in men: Clinical and pharmacological studies in men showed that the depression of fertility was completely reversible 24 weeks at the latest after discontinuation of continuous leuprorelin acetate application.